XLO

Xilio Therapeutics, Inc. [XLO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XLO Stock Summary

Top 10 Correlated ETFs

XLO

Top 10 Correlated Stocks

XLO

In the News

XLO Financial details

Company Rating
-
Market Cap
40.68M
Income
-75.03M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
73
Optionable
No
Shortable
Yes
Earnings
01 Apr 2024
P/E
-0.31
Forward P/E
-
PEG
0.21
P/S
-
P/B
0.47
P/C
-
P/FCF
-0.33
Quick Ratio
3.53
Current Ratio
3.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.73
EPS next Y
-
EPS next Q
-
EPS this Y
-12.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
4.92%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-102%
ROE
-102%
ROC
-1.38%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.49-3.45
52W High
-
52W Low
-
RSI
39
Rel Volume
0.95
Avg Volume
1.21M
Volume
1.15M
Perf Week
-5.32%
Perf Month
-1.18%
Perf Quarter
-4%
Perf Half Y
-9.58%
-
-
-
-
Beta
-0.077
-
-
Volatility
0.01%, 0.02%
Prev Close
-5.8%
Price
0.6528
Change
-4.69%

Something similar

Top by Market Cap
EMBASSY.NS
AMZN
AVGO
DHR-PB
GOOGL
Top Correlated ETFs
BSMT
BKLN
BSMR
PGX
VRP
Top Correlated Stocks
AGMH
KEWL
OMAB
ONB
PGEN
Similar Market Cap
SC0E.DE
SJ
DBPE.DE
MIND.L
CVV

Company Profile

Healthcare Biotechnology
  • Volume Average 1.21M
  • Market Capitalization 40.68M
  • Employee 73
  • CEO Dr. Rene Russo BCPS, Pharm.D.
  • Headquarters Waltham,MA,US
  • IPO Date 2021-10-22
  • Website https://www.xiliotx.com

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.